Since PSMA is over-expressed by virtually all prostate cancers, and its expression is further increased in poorly differentiated, metastatic and hormone-refractory carcinomas, it is an attractive target for diagnosis and staging of prostate cancer as well as the delivery of endoradiotherapy specifically to prostate cancer cells [5, 6]. This evidence concerns the gene FOLH1 and prostate cancer.